A booster of coronavirus vaccine Johnson & Johnson was 85% effective in preventing serious illness in areas where Omicron was dominant, a South African trial study indicated on Thursday.
The South African Medical Research Council conducted the study on health workers from 15 November to 20 December, but it has still not been peer-reviewed.
It found the top-up jab to largely protect staff in a country where the highly transmissible strain is now behind most COVID cases.
Around half a million South African health staff have received Johnson jabs as part of clinical trials.
An earlier South African study in December found the Pfizer/BioNTech vaccine to be less effective overall against Omicron, but still prevented hospital admissions by up to 70%.
More Stories
The National Treasury Should Do More To Alleviate Household Costs Of Loadshedding
Eskom Concedes That Outrage Over Power Cuts Warranted
Electricity Minister To Visit All Power Stations
Over 500 Arrested Nationwide During Protest Action
Malema Rubbishes Concerns That EFF Nationwide Protest Will Turn Violent
Santaco Says Taxi Industry Will Operate As Normal
Government Ready To Deal With Any Eventuality
Nersa Sticks By 18.65% Tariff Increase
Anarchy Will Not Be Allowed In SA – Ramaphosa
It’s Anarchy Of The Highest Order – Mbalula
Cape Town Stockpiling Diesel For Winter
ANC Is Not Corrupt – Mbalula